{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:25:38Z","timestamp":1794367538075,"version":"4.9.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Epstein-Barr virus (EBV) is associated with various types of human malignancies and with programmed death ligand (PD-L) 1 expression in neoplastic cells. However, in EBV-associated malignant lymphomas and lymphoproliferative disorders (LPDs), there is limited information regarding PD-L1 expression profiles among different histologic types and patterns of EBV latency. First, we investigated PD-L1 and EBV latent gene expression using conventional immunohistochemistry and in situ hybridization in 42 EBV-associated malignant lymphomas and LPDs. Classic Hodgkin lymphoma showed the highest PD-L1 expression with diffuse expression in all cases, followed by diffuse large B-cell lymphoma\/Burkitt lymphoma, LPDs, and extranodal NK\/T-cell lymphoma. EBV latency at the case level was not associated with PD-L1 expression. We further evaluated the expression of PD-L1 and EBV latent genes in tumor cells at single-cell resolution using multiplex fluorescence imaging. This analysis revealed that positivity rates of latent membrane protein (LMP) 1 in tumor cells were 1.0% to 89.5% (mean 35.4%) in latency type II\/III cases, and LMP1<jats:sup>+<\/jats:sup> cells showed more frequent PD-L1 expression than LMP1<jats:sup>\u2212<\/jats:sup> cells (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001, paired <jats:italic toggle=\"yes\">t<\/jats:italic> test). In contrast, no association was observed between EBV nuclear antigen 2 and PD-L1 expression. Notably, tumor cells exhibiting Hodgkin\/Reed-Sternberg cell-like morphology co-expressed PD-L1 and LMP1 more often than those that do not. Our observations suggested that LMP1 upregulates PD-L1 expression and is a potential biomarker for predicting the efficacy of immune checkpoint inhibitors. In addition, the heterogeneous expression of PD-L1 and EBV latent genes may produce diverse tumor cells with different oncogenic and immune-evasive properties, leading to resistance to targeted therapies.<\/jats:p>","DOI":"10.1097\/pas.0000000000001919","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:22Z","timestamp":1653350422000},"page":"1386-1396","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus\u2013associated Malignant Lymphomas and Lymphoproliferative Disorders"],"prefix":"10.1097","volume":"46","author":[{"given":"Ayako","family":"Kume","sequence":"first","affiliation":[{"name":"Department of Pathology, Toranomon Hospital"},{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shinozaki-Ushiku","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Division of Integrative Genomics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kunita","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/his.14379","article-title":"The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment","volume":"79","author":"Ababneh","year":"2021","journal-title":"Histopathology"},{"key":"R2-20250608","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.280342","article-title":"Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance","author":"Fisher","year":"2022","journal-title":"Haematologica"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41598-021-02515-5","article-title":"The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK\/T cell lymphoma","volume":"12","author":"Feng","year":"2022","journal-title":"Sci Rep"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3960\/jslrt.21003","article-title":"Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: a brief review","volume":"61","author":"Sakakibara","year":"2021","journal-title":"J Clin Exp Hematop"},{"key":"R5-20250608","first-page":"174","article-title":"PD1\/PD-L1 expressions in plasmablastic lymphoma with clinicopathological correlation","volume":"51","author":"Rosado","year":"2021","journal-title":"Ann Clin Lab Sci"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/pin.12950","article-title":"PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: a clinicopathological study of 50 cases","volume":"70","author":"Yamashita","year":"2020","journal-title":"Pathol Int"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/10428194.2018.1480767","article-title":"Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation","volume":"60","author":"Kinch","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12967-018-1689-y","article-title":"Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma","volume":"16","author":"Kwon","year":"2018","journal-title":"J Transl Med"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/jcm8101596","article-title":"Classical Hodgkin\u2019s lymphoma in the era of immune checkpoint inhibition","volume":"8","author":"De","year":"2019","journal-title":"J Clin Med"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"303","DOI":"10.21147\/j.issn.1000-9604.2020.03.03","article-title":"Immune checkpoint inhibitors in malignant lymphoma: advances and perspectives","volume":"32","author":"Lin","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.21873\/anticanres.14616","article-title":"EBV positivity and programmed death-ligand 1 expression in diffuse large B-cell lymphoma: a systematic review","volume":"40","author":"Barzyk","year":"2020","journal-title":"Anticancer Res"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.anndiagpath.2018.09.002","article-title":"An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours","volume":"37","author":"Wee","year":"2018","journal-title":"Ann Diagn Pathol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/his.13475","article-title":"Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells","volume":"72","author":"Sakakibara","year":"2018","journal-title":"Histopathology"},{"key":"R19-20250608","first-page":"213","article-title":"Plasmablastic lymphomas: characterization of tumor microenvironment using CD163 and PD-1 immunohistochemistry","volume":"50","author":"Ahn","year":"2020","journal-title":"Ann Clin Lab Sci"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pathol.2020.11.004","article-title":"CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients","volume":"53","author":"Antel","year":"2021","journal-title":"Pathology"},{"key":"R21-20250608","first-page":"353","article-title":"A comprehensive clinicopathologic and molecular study of 19 primary effusion lymphomas in HIV-infected patients","volume":"26","author":"Calvani","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R22-20250608","article-title":"Programmed cell death-ligand 1 (PD-L1)(+) tumour cells and low-reacting programmed cell death 1 (PD1)(+) tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus(+) diffuse large B-cell lymphoma","author":"Kimura","year":"2021","journal-title":"Clin Exp Med"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/PAS.0000000000001809","article-title":"Clinicopathologic analysis of primary adrenal diffuse large B-cell lymphoma: a reappraisal of 23 Japanese patients based on EBV association and PD-L1 expression in tumor cells","volume":"45","author":"Kawano","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000500974","article-title":"Programmed cell death 1 and programmed cell death ligands in extranodal natural killer\/T cell lymphoma: expression pattern and potential prognostic relevance","volume":"143","author":"Muhamad","year":"2020","journal-title":"Acta Haematol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/his.13857","article-title":"Clinicopathological evaluation of the programmed cell death 1 (PD1)\/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome","volume":"75","author":"Veloza","year":"2019","journal-title":"Histopathology"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/microorganisms9030603","article-title":"Epstein-Barr virus LMP1 induces soluble PD-L1 in nasopharyngeal carcinoma","volume":"9","author":"Kase","year":"2021","journal-title":"Microorganisms"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.2019000889","article-title":"EBV microRNA-BHRF1-2-5p targets the 3\u2032UTR of immune checkpoint ligands PD-L1 and PD-L2","volume":"134","author":"Cristino","year":"2019","journal-title":"Blood"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12964-019-0391-x","article-title":"Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-\u03baB, JAK1\/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma","volume":"17","author":"Vincent-Fabert","year":"2019","journal-title":"Cell Commun Signal"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","article-title":"Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas","volume":"33","author":"Anastasiadou","year":"2019","journal-title":"Leukemia"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virol.2021.02.004","article-title":"RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells","volume":"557","author":"Yanagi","year":"2021","journal-title":"Virology"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41375-019-0380-5","article-title":"Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas","volume":"33","author":"Kataoka","year":"2019","journal-title":"Leukemia"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","article-title":"EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:02:54Z","timestamp":1749416574000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001919"}},"subtitle":["A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization"],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001919","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}